Sivextro
Active Ingredient(s): Tedizolid PhosphateFDA Approved: * June 20, 2014
Pharm Company: * CUBIST PHARMS
Category: Skin Care
* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".
Sivextro Overview
Tedizolid (formerly torezolid, trade name Sivextro),[1] is an oxazolidinone-class antibiotic. Tedizolid phosphate is a phosphate ester prodrug of the active compound tedizolid. It was developed by Cubist Pharmaceuticals, following acquisition of Trius Therapeutics (originator: Dong-A Pharmaceuticals), and is marketed for the treatment of acute bacterial skin and skin structure infections (also known as complicated skin and skin-structure infections (cSSSIs)).[2]...
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tedizolid
Recent Sivextro Forums:
Be the first to start a discussion about this drug.Possible Dosages for this and Related Drugs:
Tedizolid Phosphate
- Injection: 200mg
- Powder: 200mg/vial
- Tablet: 200mg
NDC Database Records for Sivextro: (2 results)
Sorted by National Drug Code- 67919-040 Sivextro 200 mg Intravenous Powder, for Solution by Cubist Pharmaceuticals, Inc.
- 67919-041 Sivextro 200 mg Oral Tablet, Coated by Cubist Pharmaceuticals, Inc.